Literature DB >> 15642671

Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families.

Helga M Ogmundsdóttir1, Vilhelmína Haraldsdóttirm, Gudmundur M Jóhannesson, Gudrídur Olafsdóttir, Kristín Bjarnadóttir, Helgi Sigvaldason, Hrafn Tulinius.   

Abstract

BACKGROUND AND OBJECTIVES: The occurrence of two or more cases of multiple myeloma (MM) in the same family has been reported from time to time. The current study is the first population- and cancer-registry-based survey to investigate familiality of premalignant or malignant B-cell proliferation. DESIGN AND METHODS: A family registry of 218 multiple myeloma cases was compared with the records of the Icelandic Cancer Registry in order to analyze the pedigrees for the occurrence of families with multiple cases of paraproteinemia and hematologic malignancies.
RESULTS: The relative risk of developing monoclonal gammopathies of unknown significance (MGUS) was not increased among first-degree relatives of MM patients, but there was a significantly increased risk of developing MM for females separately (RR = 3.23, CI 1.17-7.01) and for males and females combined (RR = 2.33, CI 1.12-4.26). Analysis for all hematologic malignancies showed an increased risk for female relatives of MM patients (RR = 1.95, CI 1.10-3.20). Eight families were identified in which the propositus with MM had > 1 relatives with MGUS and > 1 with another hematologic malignancy, including 4 families with another relative with MM. In three families both myeloid and lymphoid malignancies occurred. INTERPRETATION AND
CONCLUSIONS: Although inheritance does not appear to be a major risk factor for the development of paraproteinemias a significant risk of developing MM was found for female relatives. The occurrence of multiple cases of benign and malignant paraproteinemias in a few families does suggest a hereditary contribution. Further studies of such families might reveal clues on pathogenesis.

Entities:  

Mesh:

Year:  2005        PMID: 15642671

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  17 in total

Review 1.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

Review 2.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

3.  Direct evidence for a polygenic etiology in familial multiple myeloma.

Authors:  Britt-Marie Halvarsson; Anna-Karin Wihlborg; Mina Ali; Konstantinos Lemonakis; Ellinor Johnsson; Abhishek Niroula; Carrie Cibulskis; Niels Weinhold; Asta Försti; Evren Alici; Christian Langer; Michael Pfreundschuh; Hartmut Goldschmidt; Ulf-Henrik Mellqvist; Ingemar Turesson; Anders Waage; Kari Hemminki; Todd Golub; Hareth Nahi; Urban Gullberg; Markus Hansson; Björn Nilsson
Journal:  Blood Adv       Date:  2017-04-07

4.  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.

Authors:  Celine M Vachon; Robert A Kyle; Terry M Therneau; Barbara J Foreman; Dirk R Larson; Colin L Colby; Tara K Phelps; Angela Dispenzieri; Shaji K Kumar; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

5.  Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.

Authors:  Ola Landgren; Sigurdur Y Kristinsson; Lynn R Goldin; Neil E Caporaso; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Magnus Bjorkholm; Ingemar Turesson
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

6.  Detection of monoclonal IGH rearrangements in circulating cells from healthy first-degree relatives of patients with multiple myeloma.

Authors:  Herbert García-Castillo; Evelia Leal-Ugarte; Pablo César Ortiz Lazareno; Esperanza Barrera-Chairez; Víctor Hugo Rosales-García; Patricio Barros-Núñez
Journal:  Med Oncol       Date:  2014-03-01       Impact factor: 3.064

7.  Familial myeloma.

Authors:  Henry T Lynch; Kelly Ferrara; Bart Barlogie; Elizabeth A Coleman; Jane F Lynch; Dennis Weisenburger; Warren Sanger; Patrice Watson; Henry Nipper; Vinetta Witt; Stephan Thomé
Journal:  N Engl J Med       Date:  2008-07-10       Impact factor: 91.245

8.  Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.

Authors:  Leah H Schinasi; Elizabeth E Brown; Nicola J Camp; Sophia S Wang; Jonathan N Hofmann; Brian C Chiu; Lucia Miligi; Laura E Beane Freeman; Silvia de Sanjose; Leslie Bernstein; Alain Monnereau; Jacqueline Clavel; Guido J Tricot; Djordje Atanackovic; Pierluigi Cocco; Laurent Orsi; James A Dosman; John R McLaughlin; Mark P Purdue; Wendy Cozen; John J Spinelli; Anneclaire J de Roos
Journal:  Br J Haematol       Date:  2016-06-22       Impact factor: 6.998

9.  Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

10.  Familial multiple myeloma: report on two families and discussion of screening options.

Authors:  Erica H Gerkes; Mirjam M de Jong; Rolf H Sijmons; Edo Vellenga
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.